Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

69.20USD
16 Nov 2018
Change (% chg)

$-0.58 (-0.83%)
Prev Close
$69.78
Open
$69.45
Day's High
$69.70
Day's Low
$68.93
Volume
8,059,111
Avg. Vol
6,555,278
52-wk High
$89.54
52-wk Low
$64.27

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $91,743.50
Shares Outstanding(Mil.): 1,293.62
Dividend: 0.57
Yield (%): 3.21

Financials

  GILD.O Industry Sector
P/E (TTM): 13.14 79.36 29.34
EPS (TTM): 5.40 -- --
ROI: 13.07 -0.30 13.58
ROE: 29.64 -2.98 15.11

Gilead 3rd quarter profit falls as hepatitis C drug sales wane

Third quarter sales of Gilead Sciences Inc's flagship hepatitis C drugs fell by more than half as competition increased, sending net profit down 22 percent from a year earlier, the U.S. biotechnology company said on Thursday.

Oct 25 2018

UPDATE 2-Gilead hepatitis C drug sales fall, but profit beats estimates

Oct 25 A steep decline in third quarter sales of Gilead Sciences Inc's flagship hepatitis C drugs was partially offset by higher sales of its HIV treatments, and the U.S. biotechnology company slightly raised its full-year sales outlook on Thursday.

Oct 25 2018

CORRECTED-UPDATE 1-Gilead hepatitis C drug sales fall, but profit beats estimates

Oct 25 Third quarter sales of Gilead Sciences Inc's flagship hepatitis C drugs fell by more than half as competition increased, sending net profit down 22 percent from a year earlier, the U.S. biotechnology company reported on Thursday.

Oct 25 2018

CORRECTED-Gilead 3rd quarter profit falls as hepatitis C drug sales wane

Oct 25 Third quarter sales of Gilead Sciences Inc's flagship hepatitis C drugs fell by more than half as competition increased, sending net profit down 22 percent from a year earlier, the U.S. biotechnology company said on Thursday.

Oct 25 2018

Gilead to launch generic versions of its hepatitis drugs

Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Sep 24 2018

Gilead to launch generic versions of its hepatitis drugs

Sept 24 Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Sep 24 2018

Brazil court strips Gilead of hepatitis C drug patent

BRASILIA/SAO PAULO A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil at the behest of a presidential candidate who pushed for the move, paving the way for cheaper generics.

Sep 24 2018

UPDATE 1-Brazil court strips Gilead of hepatitis C drug patent

BRASILIA/SAO PAULO, Sept 24 A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil at the behest of a presidential candidate who pushed for the move, paving the way for cheaper generics.

Sep 24 2018

Brazil court strips Gilead hepatitis drug patent, politician says

BRASILIA/SAO PAULO, Sept 24 A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper generics, a presidential candidate who pushed for the move said on Monday.

Sep 24 2018

UPDATE 1-Galapagos, Gilead bask in $4-6 bln new drug sales hope

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Sep 12 2018

Earnings vs. Estimates